AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.
Last trade$11.47
Day change-$0.31 (-2.63%)
Day range$11.41 – $11.88
Volume140,452
Market cap$495M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$495.4M
Price / earnings
—
Price / book
3.02×
Price / sales
1.52×
EV / sales
1.42×
EV / EBITDA
-22.47×
Profitability
Earnings per share
-$0.78
Return on assets
-13.61%
Return on equity
-20.09%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.4×
Quick ratio
1.48×
Cash ratio
0.57×
Cash flow
Price / cash flow
134.88×
Price / free cash flow
—
Free cash flow
-$1.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ANGO, quarterly periods
Line item
Q1 FY2027 Aug 31, 2026
Q4 FY2026 May 31, 2026
Q3 FY2026 Feb 28, 2026
Q2 FY2026 Nov 30, 2025
Q1 FY2026 Aug 31, 2025
Q4 FY2025 May 31, 2025
Q3 FY2025 Feb 28, 2025
Q2 FY2025 Nov 30, 2024
Revenue
$80.92M
$86.61M
$78.42M
$79.43M
$75.71M
$80.16M
$72M
$72.85M
Cost of revenue
$32.88M
$39.83M
$36.94M
$34.65M
$33.85M
$37.94M
$33.15M
$32.94M
Gross profit
$48.04M
$46.77M
$41.48M
$44.78M
$41.86M
$42.22M
$38.86M
$39.91M
Selling, general and administrative
$42.45M
$41.39M
$38.16M
$36.86M
$40.69M
$36.67M
$35.99M
$35.98M
Research and development
$7.98M
$8.18M
$7.08M
$7.77M
$6.42M
$6.59M
$6.91M
$6.43M
Total operating expenses
$55.34M
$56.97M
$54.43M
$50.91M
$52.51M
$47.73M
$48.83M
$51M
Operating income
-$7.3M
-$10.2M
-$12.95M
-$6.13M
-$10.66M
-$5.52M
-$9.97M
-$11.09M
Interest expense
$0
-$299K
$0
$0
$0
$978K
$0
$0
Income before taxes
-$7.3M
-$11.04M
-$8.07M
-$6.36M
-$10.84M
-$6.11M
-$4.41M
-$10.85M
Income taxes
-$199K
$370K
$12K
-$5K
$65K
-$60K
-$2K
-$110K
Net income
-$7.1M
-$11.41M
-$8.08M
-$6.35M
-$10.9M
-$6.05M
-$4.41M
-$10.74M
Net income attributable to common shareholders
-$7.1M
-$11.41M
-$8.08M
-$6.35M
-$10.9M
-$6.05M
-$4.41M
-$10.74M
EBITDA
-$1.8M
-$17.51M
-$838K
-$378K
-$4.71M
-$13.15M
-$369K
-$4.23M
Basic earnings per share
-$0.17
-$0.27
-$0.19
-$0.15
-$0.26
-$0.15
-$0.11
-$0.26
Diluted earnings per share
-$0.17
-$0.27
-$0.19
-$0.15
-$0.26
-$0.15
-$0.11
-$0.26
Recent news
Company coverage with links to the original publishers.
AngioDynamics (ANGO) is gaining momentum from strong NanoKnife platform performance, with revenues surging 29% to $8.3 million in fiscal Q1 2027, driven by rising prostate procedure volumes and expanded regulatory approvals. The company's Med Tech segment continues robust growth with 13.2% year-over-year revenue increase, and management expects 12%-15% Med Tech revenue growth in fiscal 2027. However, tariffs and inflation remain headwinds despite recent tariff refunds improving margins.
AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%.
AngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries.
A comprehensive market analysis report on atherectomy devices covering 39 countries with forecasts through 2036. The market is driven by the shift toward minimally-invasive techniques for treating coronary and peripheral artery diseases, replacing traditional bypass surgery. The report provides detailed market segmentation, intervention volumes, competitive dynamics, and regulatory insights across developed markets.
AngioDynamics shares fell 13.1% despite posting strong Q3 results with revenue of $79.4 million (beating estimates) and better-than-expected earnings. The sell-off was triggered by the unexpected announcement of CEO Jim Clemmer's retirement after 10 years leading the company. While the board has formed a search committee to find a successor and the company raised its 2026 guidance, investor uncertainty about leadership transition overshadowed the positive business fundamentals.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.